DNAprint Genomics (DNAG)

[mjam]

grateful - success in general... "obscene revenue" success... I took it to mean the time frame before we will be a drug company with a drug IN MARKET generating revenue... a drug matched with its accompanying response test that guarantees successful treatment... a statin or similar type?

He said both Ovanome and Statnome were "proof in principle" projects. The number of ovarian cancer patients is too small for a Taxol type drug to generate "obscene revenues", but DNAP will be saving the lives of some of the 30% of non-responders by letting them know to seek a different treatment instead of waiting to find out if the Taxol regimen is working, all the while the tumor is growing.

So I assume the "obscene revenues" will be generated by a Liptitor / statin class drug treatment with a much more common and widespread disease.